ACE and cardiovascular disorder: The question of whether preventing new-onset diabetes is associated with a reduction in cardiovascular disease events may be resolved with the results of two ongoing large-scale clinical trials – Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) (62) and ACE Inhibitor-based vs. Diuretic-based Antihypertensive Primary Treatment in Patients with PreDiabetes (ADaPT) (63).